NCT03804879 - Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

May 3, 2021

Study Completion Date

May 3, 2021

Conditions

Diabetic Nephropathy

Interventions

DRUG

Nidufexor

50 mg (two 25 mg) LMB763 capsules for oral administration

OTHER

Placebo

Placebo capsules for oral administration

DRUG

Standard of Care (SoC)

Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)

Trial Locations (18)

652

Novartis Investigative Site, Saida

1407

Novartis Investigative Site, CABA

10787

Novartis Investigative Site, Berlin

11941

Novartis Investigative Site, Amman

12206

Novartis Investigative Site, Albany

12808

Novartis Investigative Site, Prague

33014

Novartis Investigative Site, Miami Lakes

34098

Novartis Investigative Site, Istanbul

38039

Novartis Investigative Site, Talas / Kayseri

41380

Novartis Investigative Site, Kocaeli

45136

Novartis Investigative Site, Essen

73069

Novartis Investigative Site, Norman

77479

Novartis Investigative Site, Sugar Land

79935

Novartis Investigative Site, El Paso

C1056ABJ

Novartis Investigative Site, CABA

C1120AAC

Novartis Investigative Site, Buenos Aires

04910

Novartis Investigative Site, Elsterwerda

Unknown

Novartis Investigative Site, El Achrafiyé